The Australia cancer biomarkers market was valued at USD 1043.75 Million in 2025 and is expected to grow at a CAGR of 10.10%, reaching USD 2731.93 Million by 2035. The market growth is driven by the rising cancer prevalence, growing demand for early diagnosis, and increasing investment in precision oncology across the region.
Base Year
Historical Period
Forecast Period
Monash University’s 2025 immune biomarker panel will likely enhance personalized bladder cancer care, increasing biomarker-guided treatment adoption in Australia.
AI-driven models like ECU’s 2025 cancer cachexia tool are expected to boost early detection and reshape diagnostic strategies in oncology care.
Government R&D funding, such as Proteomics International’s USD 2.16 million grant, accelerates biomarker innovation and expands diagnostic capabilities nationwide.
Compound Annual Growth Rate
10.1%
Value in USD Million
2026-2035
*this image is indicative*
Australia is advancing its oncology landscape by actively investing in precision diagnostics and biomarker-driven technologies. Cancer remains a significant health challenge in Australia, with an estimated 165,000 new cases diagnosed in 2024 across various cancer types. The growing disease burden has pushed healthcare providers to adopt advanced diagnostic solutions, including biomarker-based screening and monitoring. Among all cancer types, prostate cancer continues to be one of the most commonly diagnosed in Australian men. Australia accounted for 4% of the global biomarkers market revenue in 2024, highlighting its increasing reliance on precision diagnostics to improve early detection and personalized treatment outcomes.
Immune Biomarker Innovation Set to Boost Cancer Diagnostics Market Growth
The rising demand for personalized oncology, the growing incidence of bladder cancer, and increasing research on immunotherapy resistance are driving growth in the market. For instance, in May 2025, researchers at Monash University developed a novel immune-based biomarker panel that helps predict which bladder cancer patients are unlikely to respond to BCG immunotherapy, the current gold-standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC). This panel addresses a critical clinical gap, as up to 45% of NMIBC patients show no response to treatment. The discovery is expected to boost market development by enabling earlier, biomarker-guided clinical decisions.
Major market trends include technological innovation and a rise in research funding.
AI-Based Innovations Advancing Australia Cancer Biomarker Market Development
Artificial intelligence is redefining diagnostic precision in cancer biomarker research across Australia. For instance, in April 2025, researchers from Edith Cowan University presented an AI-driven biomarker model at the AACR Annual Meeting, designed to improve early detection of cancer cachexia, a condition that affects up to 80% of patients with advanced cancer. By integrating machine learning with biomarker profiling, the model enables earlier intervention and risk assessment, positioning AI-powered tools as key drivers of biomarker innovation and diagnostics market development in Australia.
Government R&D Support Fueling Australia Cancer Biomarker Market Growth
Australia’s focus on proteomics and early cancer detection continues to gain momentum through strategic research funding. For instance, in December 2024, Proteomics International received a USD 2.16 million research and development rebate from the Australian government to accelerate its work on novel blood-based cancer diagnostic tests. The funding supports the development of protein biomarkers that can enable earlier and more accurate diagnosis. Such initiatives reflect a growing national commitment to biomedical innovation and are expected to drive significant market growth in the cancer biomarker space over the forecast period.
Protein Biomarkers to Lead the Market Share by Type
Protein biomarkers are expected to hold the largest share of the market, supported by their 67% revenue share in the historical period. This dominance stems from their widespread use in early cancer detection, disease monitoring, and treatment response assessment. Protein biomarkers offer greater accessibility, faster turnaround, and lower costs compared to genetic testing, making them a preferred option in clinical settings. With advancements in proteomic technologies and increasing demand for non-invasive diagnostics, the segment is poised to maintain its lead in the Australian market over the forecast period.
The key features of the market report comprise a funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Illumina plays a significant role in Australia’s cancer biomarkers market through its advanced next-generation sequencing (NGS) platforms, enabling early detection, diagnosis, and personalized treatment planning. Its systems support oncology research across Australian hospitals, academic centers, and private labs, driving precision medicine adoption. Collaborations with local research institutes and integration into clinical workflows enhance biomarker discovery. Growth is supported by rising government investments in genomics, improved reimbursement for molecular diagnostics, and demand for comprehensive cancer panels.
Roche is a major player in Australia’s cancer biomarkers market, combining its pharmaceuticals and diagnostics expertise to deliver targeted oncology solutions. Through its Ventana and cobas platforms, Roche offers immunohistochemistry, in-vitro diagnostics, and companion tests that guide personalized cancer therapy decisions. Strong partnerships with pathology labs and cancer centers help integrate biomarker testing into routine care. Ongoing R&D, regulatory approvals, and reimbursement support for companion diagnostics reinforce Roche’s position in Australia’s precision oncology ecosystem.
Bio-Rad supports Australian market with innovative molecular diagnostic tools, PCR-based assays, and liquid biopsy technologies that aid in early cancer detection and monitoring. Its platforms are widely used in clinical and research settings, supporting biomarker validation and oncology translational research. Bio-Rad’s strong distributor network ensures accessibility across urban and regional labs. With growing adoption of non-invasive testing and interest in multiplex assays, Bio-Rad is positioned to expand its influence in cancer diagnostics.
Qiagen contributes to Australia’s cancer biomarkers market through its sample preparation, assay technologies, and companion diagnostics that enable precise biomarker detection. Its QIAseq and QIAsymphony systems support NGS, PCR, and liquid biopsy workflows in cancer research and clinical testing. Collaborations with pharmaceutical companies strengthen its role in companion diagnostics for targeted therapies. Qiagen’s scalable solutions and regulatory-compliant products align well with Australia’s push for accessible precision medicine, especially in molecular oncology and early cancer detection programs.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Hologic, Inc., Quest Diagnostics Clinical Laboratories, Inc., and Charles River Laboratories.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Cancer Type
Market Breakup by Application
Market Breakup by Profiling Technology
Market Breakup by End User
Upto 15% Off
USD
$3099 $2789
$1999 $1799
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Cancer Type |
|
| Breakup by Application |
|
| Breakup by Profiling Technology |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share